Company / Current Liabilities
Seres Therapeutics, Inc. Current Liabilities History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$19.3M
FY2025
5-year range
$19.3M / $85.6M
FY2021-FY2025
Trend
-77.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $86M to $19M over the past 3 years.
Based on SEC 10-K filings.
$19M in FY2025 with a 10-year CAGR of +5.9%.
Improved from $86M to $19M over the past 3 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -39.1%
- 5-Year CAGR
- -16.1%
- 10-Year CAGR
- +5.9%
Key checks
Key Insights
- 5-year CAGR of -16.1%, indicating a declining trend.
- In FY2025, current liabilities decreased 77.4% year-over-year.
- Peak current liabilities was recorded in FY2023.
- Lowest current liabilities in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.18 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $19.3M | -77.4% |
| FY2023 | $85.6M | +0.0% |
| FY2022 | $85.6M | +4.1% |
| FY2021 | $82.3M | +77.2% |
| FY2020 | $46.4M | +0.9% |
| FY2019 | $46.0M | +9.4% |
| FY2018 | $42.0M | +32.9% |
| FY2017 | $31.6M | +3.8% |
| FY2016 | $30.5M | +178.9% |
| FY2015 | $10.9M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 24, 2026